Opportunity Information: Apply for PA 11 012
Apply for PA 11 012
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Toward An Improved Understanding of HDL Function, NHLBI (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837 Cardiovascular Diseases Research.
- This funding opportunity was created on Oct 25, 2010 and posted on Oct 25, 2010.
- Applicants must submit their applications by May 7, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Special district governments State governments Public housing authorities/Indian housing authorities City or township governments Small businesses County governments Public and State controlled institutions of higher education Independent school districts For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Toward An Improved Understanding of HDL Function, NHLBI (R01)" (Funding Opportunity Number PA 11 012) was a National Institutes of Health (NIH) initiative under the National Heart, Lung, and Blood Institute (NHLBI) focused on moving beyond simple measurements of HDL cholesterol levels and toward a clearer, more practical understanding of what HDL actually does in the body. The central idea behind this funding call is that HDL quantity alone has not been sufficient to explain cardiovascular risk or therapeutic benefit, so the field needs stronger, standardized ways to measure HDL function and to connect those functional readouts to underlying biology, genes, and potential interventions.
This FOA encouraged R01 research grant applications aimed at developing, validating, and standardizing laboratory assays that can reliably measure different functional properties of HDL. A key emphasis was on assays and biomarkers that capture HDL performance in biologically meaningful ways, rather than relying on static HDL-C concentration. The announcement specifically highlighted interest in innovative methods to assess functional endpoints such as in vivo reverse cholesterol transport (RCT), as well as HDL's anti-oxidant, anti-inflammatory, and anti-thrombotic activities. In practical terms, the program was seeking tools and approaches that could be used consistently across studies and laboratories, supporting comparability, reproducibility, and eventual clinical translation.
In addition to assay and biomarker development, the FOA also welcomed projects designed to identify novel genes, molecular pathways, and mechanistic targets that influence HDL function. This includes research that digs into how HDL particles achieve their protective effects, what molecular components or pathways enhance or impair those effects, and how those insights could be leveraged to define new therapeutic strategies. The scope therefore covered both methodology (how to measure HDL function well) and discovery science (what controls HDL function and how it can be modified). The opportunity also explicitly encouraged projects exploring HDL functional pathways and the discovery of new genes and therapeutics related to HDL function, signaling that applications could reasonably range from assay engineering and validation studies to mechanistic studies that connect HDL function with disease processes and intervention targets.
Administratively, this was a discretionary grant opportunity using the NIH R01 mechanism, categorized under health research with the CFDA listing 93.837 (Cardiovascular Diseases Research). It did not require cost sharing or matching funds. The FOA was posted on October 25, 2010, and had an original and current closing date of May 7, 2011, after which it was archived on June 7, 2011. While the opportunity itself is no longer open, the description reflects the priorities at the time: improving rigor and standardization in HDL functional measurements and enabling more actionable biological conclusions about HDL in cardiovascular disease.
Eligibility was broad and included many common NIH-eligible applicant types across government, academia, nonprofit, and industry. Eligible applicants included state, county, city, and special district governments; public and state-controlled and private institutions of higher education; independent school districts; public housing authorities/Indian housing authorities; small businesses; for-profit organizations other than small businesses; and nonprofits with or without 501(c)(3) status (with distinctions noted in the FOA). The FOA also specified additional eligible applicant categories such as historically Black colleges and universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities (TCCUs), faith-based or community-based organizations, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). This wide eligibility set underscored the expectation that progress in HDL functional assays and discovery could come from multiple sectors, including academic laboratories, clinical research groups, and technology-driven assay developers.
For reference, the full announcement was hosted on the NIH grants site at http://grants.nih.gov/grants/guide/pa-files/PA-11-012.html, and the posted contact pathway for technical access issues was the NIH Office of Extramural Research (OER) webmaster (FBOWebmaster@OD.NIH.GOV).
FAQs: Toward An Improved Understanding of HDL Function, NHLBI (R01) - PA-11-012
What is the grant opportunity "Toward An Improved Understanding of HDL Function, NHLBI (R01)"?
This was a National Institutes of Health (NIH) funding opportunity issued by the National Heart, Lung, and Blood Institute (NHLBI) to support R01 research projects focused on understanding what HDL does in the body (HDL function), rather than relying only on HDL cholesterol (HDL-C) levels.
What was the main purpose of this funding call?
The central purpose was to move beyond simple measurements of HDL quantity (HDL-C concentration) because HDL-C alone had not been sufficient to explain cardiovascular risk or therapeutic benefit. The FOA prioritized developing stronger, standardized ways to measure HDL function and connect those functional readouts to biology, genes, and potential interventions.
What funding mechanism did this opportunity use?
This opportunity used the NIH R01 research project grant mechanism.
What kinds of projects were encouraged under this FOA?
The FOA encouraged R01 applications that developed, validated, and standardized laboratory assays and biomarkers capable of reliably measuring different functional properties of HDL in biologically meaningful ways. It also welcomed studies identifying genes, molecular pathways, and mechanistic targets that influence HDL function.
Why did the FOA emphasize HDL function instead of HDL-C levels?
The FOA was based on the idea that measuring HDL quantity alone (HDL-C) does not adequately capture HDL's protective roles or predict cardiovascular outcomes consistently. The goal was to develop functional measurements that better reflect how HDL behaves biologically and how it may be affected by genes or interventions.
What specific HDL functional endpoints were highlighted as areas of interest?
The announcement highlighted interest in innovative methods to assess endpoints such as in vivo reverse cholesterol transport (RCT), as well as HDL's anti-oxidant, anti-inflammatory, and anti-thrombotic activities.
Did the FOA focus only on assay development?
No. In addition to assay and biomarker development, the FOA welcomed discovery-focused projects aimed at identifying novel genes, molecular pathways, and mechanistic targets that influence HDL function and could point toward new therapeutic strategies.
What was meant by "standardization" and why was it important?
Standardization referred to developing assays and approaches that could be used consistently across studies and laboratories. This was important to support comparability and reproducibility of findings and to help enable eventual clinical translation.
What types of institutions were eligible to apply?
Eligibility was broad and included many NIH-eligible applicant types across government, academia, nonprofit, and industry. Examples listed in the FOA included state, county, city, and special district governments; public and state-controlled and private institutions of higher education; independent school districts; public housing authorities/Indian housing authorities; small businesses; for-profit organizations other than small businesses; and nonprofits with or without 501(c)(3) status (with distinctions noted in the FOA).
Were minority-serving institutions and community-based organizations eligible?
Yes. The FOA listed additional eligible applicant categories such as historically Black colleges and universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities (TCCUs), and faith-based or community-based organizations.
Could non-U.S. organizations apply?
Yes. The FOA included non-U.S. entities (foreign organizations) among the eligible applicant categories.
Was cost sharing or matching required?
No. The opportunity did not require cost sharing or matching funds.
What program area and CFDA listing applied to this FOA?
It was categorized under health research and referenced CFDA 93.837 (Cardiovascular Diseases Research).
When was the FOA posted and when did it close?
The FOA was posted on October 25, 2010. The original and current closing date was May 7, 2011. It was archived on June 7, 2011.
Is this funding opportunity still open?
No. The closing date passed in 2011 and the FOA has been archived.
What did NHLBI appear to be trying to enable long-term through this program?
Based on the FOA description, the program aimed to improve rigor and standardization in HDL functional measurements and support more actionable biological conclusions about HDL in cardiovascular disease, including insights that could guide new therapeutic strategies.
Where was the full announcement posted?
The full announcement was hosted on the NIH grants site at: http://grants.nih.gov/grants/guide/pa-files/PA-11-012.html
Who was listed as the contact for technical access issues?
For technical access issues, the FOA listed the NIH Office of Extramural Research (OER) webmaster: FBOWebmaster@OD.NIH.GOV
What is the Funding Opportunity Number for this announcement?
The Funding Opportunity Number was PA 11 012 (PA-11-012).
Browse more opportunities from the same category: Health
Next opportunity: Accessible Voting Technology Initiative
Previous opportunity: Getting from Genes to Function in Lung Disease, NHLBI (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 11 012
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 11 012) also looked into and applied for these:
| Funding Opportunity |
|---|
| Sickle Cell Disease Inflammation, Thrombosis and Vascular Dysfunction, NHLBI (R01) Apply for PA 11 013 Funding Number: PA 11 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pre Travel Health Improving and Expanding the Implementation of Counseling and Surveillance of International Travelers Apply for RFA CK 11 004 Funding Number: RFA CK 11 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Affordable Care Act Family Professional Partnership/Family to Family Health Information and Education Centers Apply for HRSA 11 035 Funding Number: HRSA 11 035 Agency: Health Resources and Services Administration Category: Health Funding Amount: $95,700 |
| Alcohol marketing and youth drinking (R01) Apply for PA 11 015 Funding Number: PA 11 015 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Consortium of Lung Repair and Regeneration Building the Foundation (U01) Apply for RFA HL 12 006 Funding Number: RFA HL 12 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Lung Repair and Regeneration Consortium Administrative Coordinating Center (U01) Apply for RFA HL 12 010 Funding Number: RFA HL 12 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epidemiology and Prevention in Alcohol Research (R01) Apply for PA 11 016 Funding Number: PA 11 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epidemiology and Prevention in Alcohol Research (R21) Apply for PA 11 018 Funding Number: PA 11 018 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Epidemiology and Prevention in Alcohol Research (R03) Apply for PA 11 017 Funding Number: PA 11 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cooperative Agreements to Support Innovative Exchange Information Technology Systems Apply for IE HBE 11 001 Funding Number: IE HBE 11 001 Agency: CMS Consumer Information Insurance Oversight Category: Health Funding Amount: Case Dependent |
| State Veterans Home Construction Grant Program Apply for VA GRANTS 112508 002 Funding Number: VA GRANTS 112508 002 Agency: Construction of State Home Facilities Category: Health Funding Amount: $85,000,000 |
| The HIV Prevention with At Risk Populations Project Apply for USAID TANZANIA 11 002 RFA Funding Number: USAID TANZANIA 11 002 RFA Agency: Tanzania USAID Dar es Salaam Category: Health Funding Amount: $25,000,000 |
| Draft Program Description Request for Comments Apply for 620 10 019 Funding Number: 620 10 019 Agency: Agency for International Development Category: Health Funding Amount: $50,000,000 |
| Conducting Public Health Research Through the Field Epidemiology and Laboratory Training Programs (FETPs/FELTPs) Apply for RFA GH 11 001 Funding Number: RFA GH 11 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| USAID/Ethiopia HEAL TB Project Apply for RFA 663 11 000002 Funding Number: RFA 663 11 000002 Agency: Ethiopia USAID Addis Ababa Category: Health Funding Amount: $42,000,000 |
| Centers Program for Research on HIV/AIDS and Mental Health (P30) Apply for PAR 11 019 Funding Number: PAR 11 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Occupational Safety and Health Education and Research Centers (T42) Apply for PAR 10 217 Funding Number: PAR 10 217 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,800,000 |
| Centers of Excellence to Promote a Healthier Workforce (U19) Apply for RFA OH 11 001 Funding Number: RFA OH 11 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,300,000 |
| Exploratory Grant Program in Sudden Unexpected Death in Epilepsy (SUDEP) (P20) Apply for RFA NS 11 006 Funding Number: RFA NS 11 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Infrastructure for Maintaining Primary Care Transformation (IMPaCT) Support for Models of Multi sector, State level Excellence (U18) Apply for RFA HS 11 002 Funding Number: RFA HS 11 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 11 012", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.